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ABSTRACT  Erythrocytes are deformable cells whose shapes can be altered by treatments with 
a variety of  drugs. The forms  the erythrocyte  may assume vary continuously from  the spiny 
"echinocytes" or crenated cells at one extreme to highly folded and dented "cupped" cells at 
the other extreme. Examination of 39 compounds for cup-forming activity revealed a remarkable 
correlation between their ability to form  cupped cells and their inhibitory activity against the 
calcium regulatory protein, calmodulin. Calmodulin is known to interact with several erythro- 
cyte proteins including spectrin, spectrin  kinase, and the Ca ++ ATPase calcium  pump of the 
membrane. These proteins regulate the form of the cytoskeleton as well as intracellular calcium 
and  ATP  levels.  It  is  proposed  that  calmodulin  is  required  to  maintain  normal  en/throcyte 
morphology  and  that  in  the  presence of  calmodulin  inhibitors,  the  cell  assumes a  cupped 
shape. 
Normal erythrocytes are deformable and exhibit a wide variety 
of morphologies  which  are  functions  of their  environment. 
Bessis and others have described a continuous interchangeable 
series of erythrocyte forms from spiny "echinocytes" through 
the  familiar  biconcave  "discocytes"  to  dented  or  folded 
"cupped" cells  or "stomatocytes" (3,  10, 40).  Any given mor- 
phology represents  a  steady state  outcome of a  tendency to- 
wards  echinocytic morphology (crenation)  and  an  opposing 
tendency towards invaginated  forms (cupping).  A  variety of 
compounds having cupping and crenating properties have been 
documented (3,  10,  40)  and treatment  with combinations of 
compounds with  antagonistic  effects  generates  intermediate 
forms consistent with a steady state interpretation (10, 39). As 
a general rule, crenators are neutral or anionic compounds but 
they have a wide range of chemical structures (10).  Many are 
detergents or have membrane depolarizing properties and may 
operate via depletion of cellular stores of ATP, which is known 
to accompany crenation (4,  10). On the other hand, cup for- 
mers,  with one exception,  are all amphiphilic  cationic com- 
pounds at physiological pH and are structurally related  (10, 
40).  They have homo or heterocyclic ring systems which are 
frequently halogen or methoxy substituted and attached to the 
ring(s) is an amine (usually tertiary) containing side chain. The 
exception,  phlorrhidzine,  is  a  neutral  ring compound with  a 
fl-D-glucose side chain. 
Explanations  of the  action  of crenators  and  cup-formers 
have sought to explain their activities in terms of preferential 
partitioning  of the  compounds into  the  inner or outer lipid 
leaflets  of the  plasma  membrane.  This  would  expand  one 
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leaflet's area relative to the other and result in shape changes; 
this model is the "bilayer coupling hypothesis" (39,  40).  The 
preferential  distribution  of anionic  lipids  like  phosphatidyl 
serine in the inner membrane leaflet would favor the interca- 
lation of cationic cup formers and conversely the phosphatidyl 
choline and ethanolamine in the outer membrane leaflet would 
recruit anionic crenators (44).  By this model, nonpenetrating 
compounds which partition into the membrane would be cren- 
ators regardless of charge. Methochlorpromazine, a quaternary 
amine  crenator  of intact  cells,  becomes  a  cup-former when 
applied  to  unsealed  erythrocyte ghosts,  whereas  its  tertiary 
amine analog, clilorpromazine, is a cup former of either intact 
cells  or ghosts.  Similar  results  are  obtained  with  the  pairs: 
lidocaine and QX-222 and  HK-27 and HK-25 (39,  40).  The 
differences observed in the  action of quaternary  vs.  tertiary 
amine  analogs  on  intact  cells  could  be  explained  by  their 
different abilities to cross the plasma membrane. Similarly, in 
experiments with pairs of quaternary and tertiary local anes- 
thetics in some nerve preparations,  the quaternary analog is 
only significantly active when applied to the cytoplasmic face 
of the membrane (13, 23). 
Two observations suggest that the intercalation of drugs into 
the membrane, though important, is not sufficient to explain 
the morphological changes. First, erythrocytes incubated with 
wheat germ agglutinin (WGA), which binds to the transmem- 
brane protein, glycophorin, are reversibly immobilized in the 
echinocytic or discoid morphology which existed before WGA 
binding. They remain in this form despite changes in environ- 
ment which would normally cause a  discocyte to echinocyte 
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acetylglucosamine is  added  to  displace  the  WGA,  the  cells 
rapidly undergo the appropriate transitions. This demonstrates 
that  mobility of at least this one protein is required for shape 
changes  to occur (2).  Second,  Seeman  (37)  found  that  eryth- 
rocyte membrane expansion induced by local anesthetics and 
chlorpromazine  was ten times greater than  can be  accounted 
for  on  the  basis  of simple  intercalation  of the  compounds. 
Recent  measurements  of amphipath  concentrations  in  mem- 
branes by Conrad and  Singer (9), using the new technique of 
hygroscopic desorption,  suggest  that  the older measurements 
may  have  overestimated  membrane  concentrations  of these 
drugs.  Franks  and Lieb (12) have made recent measurements 
of  drug  concentrations  in  membranes  using  very  sensitive 
techniques.  Their  findings  addressed  the  issue  of  volumes 
occupied  by  drug  molecules  in  membranes  vs.  the  aqueous 
medium  and  found  that  there  is  little  difference.  Occupied 
volume is little more than  the volume of the drug  molecules 
themselves.  This  further  draws  attention  to  the  idea  that  a 
specific  drug  interaction  site  is  responsible  for  membrane 
"expansion" rather than a  general perturbation.  This suggests 
that  a  conformational  change  in  membrane  proteins  or  a 
change in their organization is responsible for the expansion. 
Cupping  compounds  might also affect the  state  of the  mem- 
brane  by  perturbing  the  normal  structure  of its  lipids  and 
displacing membrane-bound calcium (37). 
The results reported here,  and re-examination of published 
studies on erythrocyte shape changes in the light of recent work 
on the pharmacology of the calcium-binding protein, calmod- 
uhn,  suggest  a  different  molecular  mechanism  for  cupping. 
Specifically, calmoduhn inhibitors are found to be cup-formers 
and  the known  cup-formers are either demonstrated  calmod- 
ulin  inhibitors  or  are  structurally  very  similar  and  may  be 
characterized as suspected antagonists. This implicates calmod- 
ulin as a potential regulator of erythrocyte shape and this idea 
is developed below. 
MATERIALS  AND  METHODS 
Human erythrocytes  were washed with phosphate-buffered saline, pH 7.4 (PBS), 
and partially depleted of their ATP by overnight incubation at 37°C or 23°C to 
produce populations of ceils enhanced in proportion of echmocytes to facilitate 
scoring. The ceils were cupped by incubating them at room temperature for 15 
miu at a hematocrit of ~5% in PBS containing the test compound and fixed for 
at least 15  min with 2% glutaraldehyde in  PBS. Cupping was scored using 
Nomarski differential-interference  contrast optics on a Leitz Ortholux 1I micro- 
scope by counting the number of "cupped" ceils  with characteristic  deep concav- 
ities, irregular dimples, and deep folds, described by Bessis (3) as stomatocytes, 
spherostomatocytes, and knizocytes,  as well as multiply concave  erythrocytes  (cf. 
also Fig. 2). This type of measurement has a subjective  component but compar- 
ison of 50% effective doses (ECso'S) between separate experiments was quite 
reproducible. 
Trifluoperazine.  2HC1, trifluoperazine  sulfoxide.  2HCI, chlorpromazine.  HC1, 
chlorpromazine sulfoxide-HC1  and prochlorperazine.2HCl were obtained from 
Smith, Kline and French Laboratories (Philadelphia, PA). Fluphenazine-2HC1 
was a gift of E. R. Squibb & Sons, Inc. (Princeton, NJ). Thiothixene.HCl was 
purchased from Pfizer, Inc. (New York, NY), and Clilorprothixene.  HCI from 
Hoffmann-LaRoche (Nutley, NJ)  R24571  =  l-[bis-(p-chlorophenyl)methyl]- 
3[2,4-dichloro  beta-(2,4)dichlorobenzyloxy)-phenethyl]-imidazolium chloride 
was purchased from Janssen Pharmaceutica (Beerse, Belgium). W-7 =  N-(6- 
aminohexyl)5-chloro-l-naphthalene  sulfonamide  and W-5 = N-(6-aminohexyl)- 
l-naphthalene sulfonamide were obtained from Rikaken Co., Ltd. (Nagoya, 
Japan). Haloperidol lactate was  from McNeil Pharmaceuticals, Inc. (Spring 
House, PA). All other reagents were from Sigma ChemicaLs  (St. Louis, MO). 
RESULTS 
Exposure of erythrocytes to the calmodulin inhibitors: R2457 l, 
W7,  W5,  trifluoperazine,  trifluoperazine  sulfoxide,  chlorpro- 
mazine, chlorpromazine sulfoxide, d, 1-propranolol and others 
demonstrated sigmoid  dose-dependent induction of cup mor- 
phology with 50% effective concentrations (ECs0) ranging from 
2/tM to >1  mM (Fig.  1). The order of potency and ECs0's for 
cupping closely match the 50% inhibitory doses of these com- 
pounds  for calmodulin-dependent  enzyme activation (14,  15, 
20,  21,  22,  32,  46,  48,  49).  The  phenothiazines  and  thioxan- 
thenes,  fluphenazine,  prochlorperazine,  chlorprothixene,  and 
thiothixene  were  also  potent  cup  formers  at  concentrations 
inhibitory of calmodulin (78% to >95% cups at 30 #M). Espe- 
cially noteworthy are the  relationships  of the phenothiazines 
to their much less calmodulin antagonistic sulfoxide derivatives 
and  the relationship  of W7 to its less calmodulin  active con- 
gener,  W5.  In  every case  the  inactive  (vis-fi-vis calmodulin) 
analog was a  poorer cup-former than its active analog.  Fig. 2 
shows representative fields of unfixed erythrocytes before and 
after  incubation  with  W7  and  high  magnification  views  of 
several cells with typical cupped morphologies. 
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FIGURE  1  Cup-forming activity of £almodulin inhibitors. Seven rep- 
resentative calmodulin  inhibitors  demonstrate the sigmoid,  dose- 
dependent induction  of cupped  morphology observed with  all 14 
drugs examined in  this study.  Cells were incubated  for 15  min  in 
PBS  containing  test  compounds  and  scored  as  cupped  if  their 
morphology corresponded to those forms  defined  by Bessis (3)  as 
stomatocytes, spherostomatocytes, knizocytes or multiply concave 
erythrocytes. 50% effective doses ranged from 2 #M  to >1  mM and 
the order of cupping  potency was the same as the order of effec- 
tiveness in inhibiting calmodulin. Trifluoperazine and chlorproma- 
zine at high concentration caused significant lysis.  TFP (@) and  TFP- 
50 (C)) are abbreviations for trifluoperazine and its sulfoxide deriv- 
ative.  CPZ (&) and  CPZ50 (A)  refer to chlorpromazine and chlor- 
promazine sulfoxide.  R24571 (@),  W7 (11), and  W5 (r-I) are defined 
in Materials and Methods. Error bars are standard deviations for two 
to four determinations on at least 200 cells. 
FIGURE  2  Morphology of cupped cells. Nomarski differential-inter- 
ference  contrast  photos  of  unfixed  erythrocytes treated  with  1  x 
10  -4 M W7 in PBS. Fields contain typical populations of erythrocytes 
before (A)  and 5 rain after drug treatment (B).  C illustrates typical 
cupped  forms  seen  in  phase contrast.  In  A  cells  are  echinocytic 
because they have been depleted of their ATP to facilitate scoring 
of morphological differences. 
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Anti-CaM, Cup-forming, and Antihemolytic Activities 
Anticalmodulin activ- 
Name of compound and family  ity IDso #M and assay  Cupping ECso #M  Antihemolysis ECso #M 
Phenothiazines 
Trifluoperazine  2-10  P (20, 24, 48)  10 
C  (22,  46, 
6-50  49) 
D  (22,  48, 
1-1.5  49) 
Trifluoperazine sulfoxide  30-45  D  (48, 49)  170 
Chlorpromazine  30-42  P (20, 48)  30 
135  C (32)  10-50 (3, 10, 40) 
5.3-8  D  (48, 49) 
Yes  K (15) 
Methochlorpromazine (4 ° amine ana-  ?  100 (ghosts) crenates 
log of chlorpromazine)  intact erythrocytes (40) 
Chlorpromazine sulfoxide  2,500  P (20, 48)  >1,000 
170-250  D  (48, 49) 
Fluphenazine  13  P (20)  98% at 30 
ECho =  10 
Prochlorperazine  16  P (20)  96% at 30 
ECso -~ 10 
Promethazine  200-340  P (20, 21, 48)  ? 
D  (48, 49) 
40-60 
Thioridazine  18  P (21)  ? 
Thioxanthenes 
Chlorprothixene (cis or trans)  16  P (48)  87% at 30 
Yes  C (32)  EC5o =  10 
Thiothixene (cis or trans)  30-40  P (48)  78% at 30 
7-17  D  (48, 49)  ECso =  10 
Naphthalene sulfonamides 
W7 
W5 
Butyrophenones 
Haloperidol 
Penfluridol 
Antiadrenergics 
Propranolol (d, 1) 
Reserpine 
Antimalarials 
Mepacrine =  quinacrine 
Primaquine 
Chloroquine 
Local anesthetics 
Dibucaine =  cinchocaine 
Tetracaine 
Procaine =  novocaine 
Phenacaine 
QX-572 
Lidocaine =  xylocaine 
28  P (15, 49)  35 
51-80  K (15, 26) 
31  D*  (15) 
240  P (15, 49)  300 
230  K (15) 
210  D*  (15) 
40-60  P (20, 48) 
10  P (48) 
180  C (46) 
130-200 
56 
? 
? 
180 
190 
190 
220 
350 
440 
1,010 
920 
? 
930 
310 
4,800 
6,800 
5,800 
P (48, 49) 
C (46) 
c  (46) 
P (43) 
M  (43) 
D*  (43) 
C (46) 
P (43) 
M  (43) 
D*  (43) 
C (46) 
C (46) 
P (43) 
M  (43) 
D*  (43) 
80 
? 
175 
Yes (10) 
Yes (10) 
6o 
Yes (10, 37) 
Yes (10) 
[300]  (10) 
[300]  (10) 
Yes (10) 
? 
? 
[100] (40) 
0.97-6 (20, 37, 38) 
? 
3-19 (20, 37, 38) 
? 
200 (37) 
1.5-10  (20, 37, 38) 
1.6-6 (20, 37, 38) (eliminated 
by photolysis) 
20 (20) 
0.1-10 (38) 
22-65 (20, 37) 
25 (38) 
250 (37) 
16-20 (37, 38) 
100 (36) 
5O (36) 
3,500-5,000  (36, 38) 
? 
? 
2,000 (36) 
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Anticalmodulin  activ- 
Name of compound and family  ity IDs0 uM and assay  Cupping ECso uM  Antihemolysis ECso uM 
QX-222 (4 ° analog of Lidocaine)  ?  [100] (40) crenator  ? 
HK-27  ?  [100]  (40)  ? 
HK-25 (4  ° analog of HK-27)  ?  [100]  (40) crenator  ? 
Antianginics and vasodilators 
Prenylamine  Yes  NA (15, 49)  Yes (10)  15 (37) 
Verapamil  No  C (18)  100-400 (10)  ? 
Papaverine  250, 650  D  (48, 49)  Yes (10)  ? 
Others 
R 24571  0.5  C (14)  2  ? 
Vinblastine  Yes  P and C (45)  20 (17)  ? 
P (47) 
16 
Phlorrhidzine  ?  [250]  (10)  ? 
Benzydamine  ?  Yes (10)  ? 
The antihistamines pheniramine, brompheniramine, and bamipine are also cup-formers,  but no calmodulin related data are available (10). 
All concentrations of drugs are given in micromolar and represent 50% inhibitory or effective doses when referring to enzyme or bioassays 
and drug displacement. Bracketed values are effective doses which are not necessarily 50% values. For binding assays the value is that for Kd. 
Yes and No indicate positive or negative results, but no concentrations are given. Calmodulin assays are for: P, cyclic AMP phosphodiesterase 
from heart or smooth muscle;  C, Ca  ++ ATPase from erythrocyte membrane; K, myosin light chain kinase from smooth muscle and platelet 
or  calmodulin  dependent  protein  kinase  from  synaptosomes;  D,  direct  binding  of  radioactive  compound  to  purified  calmodulin  or 
displacement of tritiated trifluoperazine by an unlabeled compound (D* is displacement of tritiated W7).  NA means no assay was explicitly 
referred to in the reference and  ? means no data are presently available. Underlined values under cupping refer to new data presented here 
and  the  assay  is  described  in  the  text.  Antihemolysis  refers  to  protection  of  erythrocytes  against  hypotonic  lysis  and  is  measured 
colorimetrically for hemoglobin release. Numbers in parentheses are references. 
We have compared 39 compounds for their anticalmodulin, 
cup-forming and antihemolytic activities where known. Table 
I summarizes the observations available in the literature  and 
includes new data on the cup forming activity of 14 calmodulin 
inhibitors. Protection against hypotonic lysis is correlated with 
the ability  of compounds to form cups and with  membrane 
expansion; it is a useful indicator of which compounds, not yet 
tested for cupping ability, are likely candidates for having this 
activity (37, 38). Landry et al. (20) have also shown a correla- 
tion between membrane stabilization (antihemolytic activity) 
and anticalmodulin  activity for several phenothiazines and a 
butyropbenone.  Antihemolysis is measured  by the degree to 
which  erythrocytes  are  protected  by  drugs  against  lysis  in 
hypotonic saline with subsequent release of hemoglobin (meas- 
ured colorimetrically). Examination of the table reveals a re- 
markable correlation between the three properties of cupping, 
antihemolysis, and calmodulin inhibition. The order of  potency 
of the various compounds is similar  for the three  properties 
and  the effective doses are of the same order of magnitude. 
Where the data are available, every compound known to be a 
calmodulin inhibitor was found to be a cup-former. Similarly, 
where  examined,  all  known  cup  formers  were  calmodulin 
inhibitors with the one exception of verapamil. It is a calcium 
channel  blocker  and  might  prevent  calmodulin  activity  by 
blocking its access to calcium. Observations on three pairs of 
quaternary/tertiary  amine  analogs illustrate  the  finding that 
the site  of cupping activity is on the inside of the membrane 
(40). Unsealed ghosts are cupped but intact cells are crenated 
by the  quaternary  analog,  whereas  the  tertiary  analog  cups 
both ghosts and cells. Fig. 3 presents the structures of the drugs 
tested and shows the structural similarities between compounds 
in each family and between groups. 
DISCUSSION 
Based on the interactions of calmodulin with erythrocyte cy- 
toskeletal proteins and the action of calmodulin antagonists as 
cup formers, we postulate that the control of erythrocyte shape 
is under regulation by calmodulin. This would result from its 
direct  and  indirect  effects on the spectrin-actin cytoskeleton 
and by control of intracellular ATP and Ca  ++ levels. 
A  cytoskeleton consisting of the proteins: spectrin, ankyrin 
(and other syndeins), band 4.1,  and actin is connected to the 
erythrocyte membrane on its cytoplasmic face via the trans- 
membrane protein band 3 (5). Factors which control the assem- 
bly, state  of polymerization, and organization of these cyto- 
skeletal elements control the cell's shape (5). 
Recently it  has  been  demonstrated  that  calmodulin  binds 
specifically and tightly to spectrin and although the function 
of this binding has not yet been ascertained, it is likely that it 
would modulate the state of polymerization or interaction of 
spectrin with actin and other proteins (42). 
Phosphorylation of spectrin band 2 has been correlated with 
spectrin-actin  interaction  and  morphological transformation 
from discocyte to echinocyte in erythrocyte ghosts,  but  this 
point is somewhat controversial (1, 4, 29,  30).  Spectrin phos- 
phorylation is regulated by calcium via a calmodulin-depend- 
ent spectrin kinase which is inhibitable  in vitro by the com- 
monly used calmodulin inhibitor, trifluoperazine (a potent cup- 
former) (16). Since calmodulin inhibitors affect spectrin phos- 
phorylation, it is thus likely that they should antagonize echin- 
ocyte formation and favor stomatocytes as is actually observed. 
Calmodulin dependent phosphorylation of several membrane 
proteins has been demonstrated in a variety of cell types and 
is not unique to spectrin (35). If the phosphoproteins ankyrin 
and band 4.1 use such calmodulin regulated kinases they may 
also be able to regulate red cell cytoskeletal organization in an 
analogous fashion to spectrin. 
The level of intracellular ATP has been shown to be related 
to the erythrocyte's shape. ATP depleted cells are echinocytic 
but return to discocyte form upon restoration of normal ATP 
levels (11,  28,  31).  Increasing internal calcium levels such as 
with  the  ionophore A23187  also produces echinocytes. This 
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FIGURE 3  Drug structures. Summary of structures of cup forming and calmodulin inhibiting drugs whose activities are summarized 
in Table  1.  (A)  Phenothiazines.  (B)  Phenothiazine sulfoxides.  (C)  Thioxanthenes. R1  and  R2 substitutions are for A-C.  (D) 
Mepacrine equals Quinacrine. (E) Naphthalene sulfonamides W7 (R = CI) and W5 (R = H). (F) Propranolol.  (G) Chloroquine. (H) 
Dibucaine equals Cinchocaine. (I) Primaquine.  (J)  HK 27 (3  ° amine) and HK 25 (4  ° amine). (K) Verapamil.  (L) QX 572. (M) 
Procaine (R = H) and Tetracaine (R =  C4H9). (N) Phenacaine. (O) Prenylamine.  (P) Lidocaine (3 ° amine) and QX 222 (4  ° amine). 
(Q)  Phloridzin  equals  Phlorrhidzine.  (R)  Reserpine.  (5)  Benzydamine.  (T)  Papaverine.  (U)  Vinblastine.  (V)  R24571. (W) 
Haloperidol. (X) Penfluridol. 
effect may be secondary to a depletion of cellular ATP which 
is hydrolysed by the membrane bound calcium ATPase pump 
(11). The ion pump binds and is regulated by calmodulin and 
influxes of calcium stimulate its activity (14, 25). Calmodulin 
inhibitors should reduce Ca  ++ pump activity and thereby retard 
ATP depletion. This would favor cupped morphology. Fur- 
thermore,  calmodulin  inhibitors  bind  to  calmodulin  in  its 
calcium loaded configuration and prevent Ca  ++ release. This 
would have the effect of keeping free calcium levels low. ATP 
depletion and calcium influx also lead to two types of cross- 
linking of cytoskeletal proteins into very high molecular weight 
complexes and should thereby stabilize the cell's morphology 
(27, 28, 41). 
At least three routes of calmodulin regulation of cell shape 
are therefore possible in the erythrocyte: (a) binding of cal- 
modulin to spectrin which alters its state of polymerization or 
association with cytoskeletal proteins; (b) modulation of spec- 
trin phosphorylation via the  calmodulin-dependent spectrin 
kinase; and (c) regulation of ionic environment and ATP levels 
via the calcium ATPase calcium pump or the ability of cal- 
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Calmodulin activity would be necessary for the stomatocyte 
to discocyte and discocyte to echinocyte  transformations.  In- 
hibitors of this activity would result in opposing morphological 
transformations due to restoring forces generated  by the cal- 
modulin "off" configuration of the cytoskeleton.  This model 
can account for the activity of the known cup-forming drugs. 
However, the intercalation  of drugs into the outer membrane 
leaflet may still be the appropriate explanation for the actions 
of many  crenators.  Brewer  et  al.  (7)  has  previously  drawn 
attention to the correlation between antihemolytic activity and 
CaM-inhibitory activity of several drugs. However, his earlier 
model (6) to explain how CaM might control erythrocyte shape 
is inconsistent with more recent findings. It was proposed that 
CaM  and  phosphorylation  had  antagonistic  effects  on  the 
spectrin lattice which determined cell shape. It is now known 
(16) that CaM actually promotes spectrin phosphorylation via 
a  CaM-dependent  spectrin  kinase,  so  their effects  should  be 
similar. 
There are other examples of cell surface and shape regulation 
by  calmodulin  which  establish  a  precedent  for  our  model. 
Platelet  shape and binding of Von Willebrand factor VIII to 
surface receptors are strongly affected by calmodulin inhibitors 
trifluoperazine and chlorpromazine, but not by their inactive 
sulfoxide derivatives (19). Surface antigen capping on lympho- 
cytes is inhibited by local anesthetics and phenothiazines and 
calmodulin redistributes with the underlying cytoskeleton (24, 
33,  34).  In  3T3  and  other  cultured  mammalian  cells,  local 
anesthetics,  and phenothiazines alter the cell shape and cause 
a  loss  of microf'flaments  from  the  membrane  (8,  31).  Thus, 
regulation of cell shape at the level of membrane-cytoskeletal 
interaction may be a general role for calmodulin. 
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